Streetbeat News

Stock Prices

MSTR

MicroStrategy's stock is trading higher following the company's announcement of purchasing Bitcoin worth approximately $616 million.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:26 pm

FANH

PUYI

Puyi Inc. shares have seen an uptick following the announcement that shareholders of Fanhua Inc. have entered into share exchange agreements with Puyi.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:26 pm

HALL

Hallmark Financial Services' shares continue to trade lower following the company's announcement on December 26 about its intention to voluntarily delist from the Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:15 pm

FWBI

First Wave BioPharma, Inc. shares have resumed trading after a temporary halt. The resumption of trading allows investors to buy and sell FWBI stock again.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:14 pm

AMD

AMD has released six patches for the Power Management Controller driver on Linux, likely for the upcoming Zen 5 CPUs. These patches suggest preparation for an earlier 2024 release compared to previous Zen generations. The Zen 5 is expected to feature the Navi/RDNA 3.5 iGPU architecture, which could outperform Intel's Meteor Lake's Arc graphics in Linux and influence the gaming hardware market, including devices like the Steam Deck 2.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:13 pm

FWBI

First Wave BioPharma's stock (FWBI) was halted on a circuit breaker due to a rapid downside movement but has since recovered, now showing an increase of 90%.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:04 pm

CVRX

Lake Street has reaffirmed its Buy rating on CVRx (NASDAQ:CVRX) and increased its price target from $21.00 to $32.00. CVRx's stock is currently trading at $31.44, up 1.29% over the last 24 hours. The new price target suggests a modest 1.78% potential upside. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its main product, Barostim, targeting the Autonomic Nervous System to treat heart failure.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 5:00 pm

FWBI

First Wave BioPharma, Inc. (FWBI) has entered into agreements with certain warrant holders to exercise their warrants for 881,337 shares at a reduced price of $5.50 per share, resulting in gross proceeds of approximately $4.8 million. The company also issued new warrants in this private placement, which was structured as an at-market transaction under Nasdaq rules. Roth Capital Partners served as the financial advisor for the transaction.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:57 pm

CHRS

Coherus BioSciences, Inc. (NASDAQ:CHRS) stock is rising after announcing FDA approval for its Udenyca Onbody pegfilgrastim delivery device. The device offers an automatic delivery option for medication, complementing existing administration methods. High short interest in CHRS shares could lead to larger stock movements following such positive catalysts.

Portfolio Pulse from Erica Kollmann

December 27, 2023 | 4:54 pm

AIR

AAR Corp (NYSE:AIR) has expanded its flight-hour component support agreement with ASL Aviation Holdings DAC, increasing the number of supported aircraft from 28 to 65. The contract now includes ASL Airlines from Belgium, France, the United Kingdom, and Ireland. AAR's Integrated Solutions will provide 24/7 support for the airlines' 737 fleets. Financial details of the deal were not disclosed. AAR's stock was trading slightly lower at the time of the report.

Portfolio Pulse from Shivani Kumaresan

December 27, 2023 | 4:50 pm